NCT06958627 2025-05-06
any
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2/3 Recruiting
Clinical Trials
7 trialsNCT06868017 2025-03-10
Randomized Controlled Clinical Study of Efficacy and Safety of Initumab Combined with Pyrrotinib and Chemotherapeutic Agents in Neoadjuvant Therapy for HER2-positive Breast Cancer with Different Treatment Cycles
The First Hospital of Jilin University
Phase 4 Not yet recruiting
NCT02705859 2025-01-09
Panther
Cancer Trials Ireland
Phase 1 Completed
NCT02476539 2024-03-01
Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 1 Completed
NCT03735966 2022-12-01
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Docetaxel and Carboplatin in HER2 Positive Breast Cancer Patients.
Henan Cancer Hospital
Phase 2 Completed
NCT02362958 2020-07-15
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03947242 2019-05-15
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
Henan Cancer Hospital
Phase NA Unknown